



PTO/SB/17 (10-03)

Approved for use through 07/31/2006. OMB 0651-0032  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# FEE TRANSMITTAL for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

 Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$ 180.00)

## Complete if Known

Application Number	08/921,060
Filing Date	August 29, 1997
First Named Inventor	DARRELL R ANDERSON
Examiner Name	Ronald Schwadron
Art Unit	1644
Attorney Docket No.	037003-0275463

## METHOD OF PAYMENT (check all that apply)

 Check  Credit card  Money Order  Other  None
 Deposit Account:

Deposit Account Number 033975  
 Deposit Account Name PILLSBURY WINTHROP LLP

The Director is authorized to: (check all that apply)

Charge fee(s) indicated below  Credit any overpayments  
 Charge any additional fee(s) or any underpayment of fee(s)  
 Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

## FEE CALCULATION

## 1. BASIC FILING FEE

Large Entity Fee Code (\$)	Fee	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001	770	2001	385	Utility filing fee
1002	340	2002	170	Design filing fee
1003	530	2003	265	Plant filing fee
1004	770	2004	385	Reissue filing fee
1005	160	2005	80	Provisional filing fee
<b>SUBTOTAL (1) (\$)</b>				<b>0.00</b>

## 2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims	-20** =	X	=
Multiple Dependent	- 3** =	X	=

Large Entity Fee Code (\$)	Fee	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1202	18	2202	9	Claims in excess of 20
1201	86	2201	43	Independent claims in excess of 3
1203	290	2203	145	Multiple dependent claim, if not paid
1204	86	2204	43	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent
<b>SUBTOTAL (2) (\$)</b>				<b>0.00</b>

\*\*or number previously paid, if greater; For Reissues, see above

## 3. ADDITIONAL FEES

Large Entity Small Entity

Fee Code (\$)	Fee	Fee Code (\$)	Fee Description	Fee Paid
1051	130	2051	65 Surcharge - late filing fee or oath	
1052	50	2052	25 Surcharge - late provisional filing fee or cover sheet	
1053	130	1053	130 Non-English specification	
1812	2,520	1812	2,520 For filing a request for ex parte reexamination	
1804	920	1804	920* Requesting publication of SIR prior to Examiner action	
1805	1,840	1805	1,840* Requesting publication of SIR after Examiner action	
1251	110	2251	55 Extension for reply within first month	
1252	420	2252	210 Extension for reply within second month	
1253	950	2253	475 Extension for reply within third month	
1254	1,480	2254	740 Extension for reply within fourth month	
1255	2,010	2255	1,005 Extension for reply within fifth month	
1401	330	2401	165 Notice of Appeal	
1402	330	2402	165 Filing brief in support of an appeal	
1403	290	2403	145 Request for oral hearing	
1451	1,510	1451	1,510 Petition to institute a public use proceeding	
1452	110	2452	55 Petition to revive - unavoidable	
1453	1,330	2453	665 Petition to revive - unintentional	
1501	1,330	2501	665 Utility issue fee (or reissue)	
1502	480	2502	240 Design issue fee	
1503	640	2503	320 Plant issue fee	
1460	130	1460	130 Petitions to the Commissioner	
1807	50	1807	50 Processing fee under 37 CFR 1.17(q)	
1806	180	1806	180 Submission of Information Disclosure Stmt	180.00
8021	40	8021	40 Recording each patent assignment per property (times number of properties)	
1809	770	2809	385 Filing a submission after final rejection (37 CFR 1.129(a))	
1810	770	2810	385 For each additional invention to be examined (37 CFR 1.129(b))	
1801	770	2801	385 Request for Continued Examination (RCE)	
1802	900	1802	900 Request for expedited examination of a design application	
Other fee (specify)				
*Reduced by Basic Filing Fee Paid				<b>SUBTOTAL (3) (\$)</b>
				<b>180.00</b>

SUBMITTED BY

(Complete if applicable)

Name (Print/Type)	Thomas A. Cawley, Jr.	Registration No. (Attorney/Agent)	40944	Telephone	(703) 905-2144
Signature				Date	March 18, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In Re the Application of  
ANDERSON et al.  
Application No.: 08/921,060

Filed: August 29, 1997

Group Art Unit: 1644

Examiner: Ronald B. Schwadron

Confirmation No.: 9119

For: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED ANTIBODIES  
TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION ANTIGEN FOR  
TREATMENT OF B CELL LYMPHOMA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached, with the exception of the following documents: (1) items marked with an asterisk are of record in U.S. Application No. 07/978,891, to which the instant application claims priority under 35 U.S.C. § 120; and (2) related international application PCT/US93/10953, published as WO 94/11026, and related U.S. patents, both of which claim priority U.S. Application No. 08/149,099, to which the instant application also claims priority under 35 U.S.C. § 120. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of the first official action on the merits, but before the mailing date of a final rejection or notice of allowance. Payment of the requisite fee under 37 CFR 1.17(p) is enclosed.

Respectfully submitted,




Thomas A. Cawley, Jr., Ph.D.  
Registration Number 40,944

Date: March 18, 2004  
PILLSBURY WINTHROP LLP  
Telephone: (703) 905-2000  
Facsimile: (703) 905-2500  
P.O. Box 10500  
McLean, VA 22102  
TAC/JBM:ntb

00

FORM PTO-1449 (modified) To: U.S. Department of Commerce (PW FORM PAT-1449) Patent and Trademark Office				Atty. Dkt. No.	M#	Client Ref.
					0275463	1992-30-0029CP2
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Applicant: ANDERSON et al.		
				Appln. No.: 08/921,060		
				Filing Date: August 29, 1997		
Date: March 18, 2004				Examiner: Schwadron, R.	Group Art Unit: 1644	



U.S. PATENT DOCUMENTS							
Examiner's Initials*		Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
	AR	5,595,721	01/1997	KAMINSKI			
	BR	5,439,665	08/1995	HANSEN			
	CR	RE 38,008	02/2003	ABRAMS			
	DR	5,736,137	04/1998	ANDERSON			
	ER	5,776,456	07/1998	ANDERSON			
	FR	5,843,439	12/1998	ANDERSON			
	GR	6,399,061	06/2002	ANDERSON			
	HR	6,682,734	01/2004	ANDERSON			

#### FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
	IR	WO 94/11026	05/1994	PCT	ANDERSON		
	JR						
	KR						
	LR						
	MR						

#### OTHER

*	NR	Grossbard M.L., et al., "Monoclonal antibody-based therapies of leukemia and lymphoma," <i>Blood</i> , 1992, 80:863-878.
*	OR	Tedder T.F., et al., "Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes," <i>Eur J Immunol</i> , 1986, 16(8):881-87.
*	PR	Tedder T.F., et al., "Cloning of a complementary DNA encoding a new mouse B lymphocyte differentiation antigen, homologous to the human B1 (CD20) antigen, and localization of the gene to chromosome 19," <i>J Immunol</i> , 1988, 141(12):4388-94.
	QR	
	RR	
	SR	
	TR	
	UR	

Examiner	Date Considered:
----------	------------------

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.